A GOP lawmaker asked the Trump administration to restrict outbound investment into China’s biotech sector, arguing that expanded capital flows could strengthen strategic capabilities and increase risk. The request targets dealmaking that has become a meaningful channel for US investor participation in China’s drug and diagnostics landscape. The same policy direction is reflected in broader discussions about limiting certain forms of outbound investment and extending those restrictions to biotechnology. For companies and investors, the move raises the probability of more compliance burden, reduced cross-border collaboration optionality, and tighter review of future transactions. Separately, China announced new investigator-initiated trial (IIT) rules intended to tighten oversight while legitimizing pathways for modalities beyond cell and gene therapies, suggesting regulators are reshaping how trials are conducted rather than halting research.